UBS Group’s Celularity Inc CELUW Stock Holding History

UBS Group’s Portfolio CELUW Stock Details CELUW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22	Buy	2,215 +302	+16%	+$3	﹤0.01%	10279
2025 Q4	$31	Buy	1,913 +600	+46%	+$15	﹤0.01%	10315
2025 Q3	$46	Buy	+1,313	New	+$64	﹤0.01%	10035
2024 Q4	–	Sell	-168	Closed	-$2	–	9964
2024 Q3	$2	Buy	168 +68	+68%	+$1	﹤0.01%	9409
2024 Q2	$2	Buy	+100	New	+$3	﹤0.01%	9417
2024 Q1	–	Sell	-38,556	Closed	-$1.54K	–	9383
2023 Q4	$1.54K	Buy	+38,556	New	+$663	﹤0.01%	8280
2023 Q1	–	Sell	-18,446	Closed	-$1.29K	–	9655
2022 Q4	$1.29K	Buy	18,446 +18,438	+230,475%	+$4.04K	﹤0.01%	9903
2022 Q3	$0	Hold	8	–	–	﹤0.01%	10385
2022 Q2	$0	Sell	8 -3,566	-100%	-$3.51K	﹤0.01%	10367
2022 Q1	$5K	Buy	3,574 +3,566	+44,575%	+$2.9K	﹤0.01%	9104
2021 Q4	$0	Hold	8	–	–	﹤0.01%	10282
2021 Q3	$0	Hold	8	–	–	﹤0.01%	9580
2021 Q2	$0	Buy	+8	New	+$10	﹤0.01%	9410
2021 Q1	–	Sell	-3,067	Closed	-$9K	–	9025
2020 Q4	$9K	Buy	+3,067	New	+$5.75K	﹤0.01%	7552

Other funds holding CELUW

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

PEAK6 Chicago, Illinois $42.6B AUM 66.3% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group's CELUW Position: Q1 2026 in Review

UBS Group increased its Celularity Inc (CELUW) stake by 16% in Q1 2026, buying an estimated $3 and bringing the position to 2,215 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #10279.

UBS Group first reported a position in CELUW in Q4 2020 and has held it in 14 quarters since. The position peaked at $9K in Q4 2020. 14 funds tracked by Wall St. Rank hold CELUW as of Q1 2026.

UBS Group held 2,215 shares of Celularity Inc worth $22 as of Q1 2026.
UBS Group bought 302 Celularity Inc shares in Q1 2026, an estimated $3.
Celularity Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10279 holding.
UBS Group first reported a position in Celularity Inc in Q4 2020 and has held it in 14 quarters since.
UBS Group's Celularity Inc position peaked at $9K in Q4 2020.
14 funds tracked by Wall St. Rank held Celularity Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.